Albert Bourla, Pfizer’s chairman and CEO, will receive the 2024 the American Association for Cancer Research Outstanding Achievement Award for Service to Cancer Science and Medicine during the AACR Annual Meeting 2024, to be held April 5-10 in San Diego, California.
The phase III PATINA trial demonstrated that the addition of Ibrance (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival by investigator assessment in patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer.
